Journal
AMERICAN JOURNAL OF KIDNEY DISEASES
Volume 72, Issue 5, Pages 634-643Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2018.04.019
Keywords
-
Categories
Funding
- Amgen
- Kyowa Hakko Kirin
- Baxter Healthcare
- AstraZeneca
- European Renal Association-European Dialysis and Transplant Association
- German Society of Nephrology
- Hexal AG
- Janssen
- Japanese Society for Peritoneal Dialysis
- Keryx
- Proteon
- Relypsa
- Roche
- Societa Italiana di Nefrologia
- Spanish Society of Nephrology
- Vifor Fresenius Medical Care Renal Pharma
- National Health and Medical Research Council
- Canada
- Canadian Institutes of Health Research
- Ontario Renal Network
- France
- Agence Nationale de la Recherche
- Thailand
- Thailand Research Foundation
- Chulalongkorn University Matching Fund
- King Chulalongkorn Memorial Hospital Matching Fund
- National Research Council of Thailand
- United Kingdom
- National Institute for Health Research by the Comprehensive Clinical Research Network
- United States
- National Institutes of Health and Patient-Centered Outcomes Research Institute
Ask authors/readers for more resources
Rationale & Objective: Missed hemodialysis (HD) treatments not due to hospitalization have been associated with poor clinical outcomes and related in part to treatment nonadherence. Using data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) phase 5 (2012-2015), we report findings from an international investigation of missed treatments among patients prescribed thrice-weekly HD. Study Design: Prospective observational study. Setting & Participants: 8,501 patients participating in DOPPS, on HD therapy for more than 120 days, from 20 countries. Longitudinal and cross-sectional analyses were performed based on the 4,493 patients from countries in which 4-month missed treatment risk was > 5%. Predictors: The main predictor of patient outcomes was 1 or more missed treatments in the 4 months before DOPPS phase 5 enrollment; predictors of missed treatments included country, patient characteristics, and clinical factors. Outcomes: Mortality, hospitalization, laboratory measures, patient-reported outcomes, and 4-month missed treatment risk. Analytical Approach: Outcomes were assessed using Cox proportional hazards, logistic, and linear regression, adjusting for case-mix and country. Results: The 4-month missed treatment risk varied more than 50-fold across all 20 DOPPS countries, ranging from < 1% in Italy and Japan to 24% in the United States. Missed treatments were more likely with younger age, less time on dialysis therapy, shorter HD treatment time, lower Kt/V, longer travel time to HD centers, and more symptoms of depression. Missed treatments were positively associated with all-cause mortality (HR, 1.68; 95% CI, 1.37-2.05), cardiovascular mortality, sudden death/cardiac arrest, hospitalization, serum phosphorus level > 5.5 mg/dL, parathyroid hormone level > 300 pg/mL, hemoglobin level < 10 g/dL, higher kidney disease burden, and worse general and mental health. Limitations: Possible residual confounding; temporal ambiguity in the cross-sectional analyses. Conclusions: In the countries with a 4-month missed treatment risk > 5%, HD patients were more likely to die, be hospitalized, and have poorer patient-reported outcomes and laboratory measures when 1 or more missed treatments occurred in a 4-month period. The large variation in missed treatments across 20 nations suggests that their occurrence is potentially modifiable, especially in the United States and other countries in which missed treatment risk is high.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available